Acceleron Pharma Inc. (XLRN): Price and Financial Metrics
GET POWR RATINGS... FREE!
XLRN Stock Price Chart Interactive Chart >
XLRN Price/Volume Stats
|Current price||$178.75||52-week high||$189.99|
|Prev. close||$179.68||52-week low||$108.82|
|Day high||$179.85||Avg. volume||572,759|
|50-day MA||$168.57||Dividend yield||N/A|
|200-day MA||$137.67||Market Cap||10.93B|
Acceleron Pharma Inc. (XLRN) Company Bio
Acceleron Pharma XLRN is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Most Popular Stories View All
XLRN Latest News Stream
|Loading, please wait...|
XLRN Latest Social Stream
View Full XLRN Social Stream
Latest XLRN News From Around the Web
Below are the latest news stories about Acceleron Pharma Inc that investors may wish to consider to help them evaluate XLRN as an investment opportunity.
Sphinx Trading LP bought a new stake in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 700 shares of the biopharmaceutical companys stock, valued at approximately $120,000. Several other large investors also recently added to or reduced 
The purchase of Acceleron Pharma gives Merck one more arrow in its quiver as it prepares for the patent on its blockbuster cancer therapeutic Keytruda to expire.
No summary available.
Acceleron Pharma (NASDAQ:XLRN) and Brickell Biotech (NASDAQ:BBI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Insider and Institutional Ownership 90.4% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 14.2% 
Fulton Bank N.A. bought a new stake in Acceleron Pharma Inc. (NASDAQ:XLRN) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,507 shares of the biopharmaceutical companys stock, valued at approximately $260,000. Other institutional investors and hedge funds have also recently made changes to 
XLRN Price Returns